Divarasib
Product Specifications
UNSPSC Description
Divarasib (GDC-6036) is an orally bioavailable, highly potent, and selective KRAS G12C inhibitor with an IC50 of <0.01 μM. Divarasib covalently binds to the switch II (SW-II) pocket of KRAS G12C and irreversibly locks it in the inactive GDP-bound state.
Target Antigen
Ras
Type
Reference compound
Related Pathways
GPCR/G Protein;MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/divarasib.html
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NC1=N[C@]([C@]2=C(C=C3C(N=C(N=C3N4[C@H](CN(CC4)C(C=C)=O)C)OC[C@H]5N(CCC5)C)=C2F)Cl)=C(C(C)=C1)C(F)(F)F
Molecular Weight
622.06
References & Citations
[1]Sushant Malhotra, et al. Fused ring compounds. WO2020097537A2.|[2]Lingyao Meng, et al. Assessment of KRAS G12C Target Engagement by a Covalent Inhibitor in Tumor Biopsies Using an Ultra-Sensitive Immunoaffinity 2D-LC-MS/MS Approach. Anal Chem. 2022 Sep 20;94(37):12927-12933.
Shipping Conditions
Room Temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-145928/Divarasib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-145928/Divarasib-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
2417987-45-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
14418141 1x10<sup>6</sup> cells/1.0ml
C2orf60 CRISPR Knock Out 293T Cell Line (Human)
Ask
View Details 